FDA Approves Beren's LEMBAZ, First Drug to Improve Survival in Infantile NPC
The FDA has approved LEMBAZ (adrabetadex), making it the first medicine to tackle the underlying cholesterol-trafficking defect behind Niemann-Pick disease type C and the first to improve survival in the infantile-onset form. Beren Therapeutics says the drug hits commercial sites nationwide in early December, backed by new family support programs.
- 2 sources report it: aol.com, finance.yahoo.com.
- The source published it on Nov 17, 2026 at 11:05 AM.
Nothing open. Every check passed.
The U.S. Food and Drug Administration approved LEMBAZ (adrabetadex) for adults and children with Niemann-Pick disease type C whose neurological symptoms began before age 6, Beren Therapeutics announced Nov. 17, 2026. It's the first medicine to address the cholesterol-trafficking defect that causes NPC and the first to improve survival in infantile-onset NPC. Beren also picked up a Priority Review Voucher with the green light.
The approval rests on an overall survival analysis of I-NPC patients treated with LEMBAZ across three clinical studies and an Expanded Access Program, compared against matched external controls. The FDA determined that comparison served as the adequate and well-controlled study backing the decision. The data showed a 55 percent reduction in the risk of mortality.
NPC is a rare, devastating neurodegenerative disorder in which defective proteins fail to transport cholesterol inside cells, trapping it and starving the brain and nervous system. LEMBAZ works by re-establishing that intracellular cholesterol trafficking. Elizabeth M. Berry-Kravis, M.D., Ph.D., of Rush University Medical Center and lead investigator for the Expanded Access Program, said lost neurological function can't be regained, making early diagnosis and treatment critical, and that the drug gives children more time to be children.
Heather Moran-Teal, Executive Director of the National Niemann Pick Disease Foundation, called the approval a new kind of hope for families who know how precious time can be. Beren CEO Jason Camm credited nearly two decades of work by the global NPC community and five years of collaboration with the FDA to build a rigorous way to evaluate more than a decade of clinical evidence.
LEMBAZ lands at commercial sites nationwide in early December, and Beren has rolled out LEMBAZ Family Support and a Caregiver Ambassador Program to get families there. The support arm offers full out-of-pocket assistance for eligible families, case managers to coordinate insurance and travel logistics, and a Family Access Manager as a single point of contact to find a site of care close to home. Bennett Smith, Beren's Senior Vice President of Commercial, said proximity to an administration site should never stand between a family and treatment.
The label carries a boxed warning: treatment has caused permanent hearing impairment, ranging from mild to profound hearing loss, including in people whose hearing was normal beforehand. It is not known whether continuing or lowering the dose affects the risk of further hearing loss, and healthcare providers will not increase the dose if hearing tests show impairment beyond a set limit.
TopicsBeren Therapeutics · LEMBAZ · adrabetadex · FDA · Niemann-Pick disease type C · Heather Moran-Teal · Elizabeth M. Berry-Kravis · Jason Camm
Written by AI from verified reporting.
More stories
- Health & science medicalxpress.com 1 viewFDA clears Sunharbo, first factor XIa inhibitor to prevent second strokes
- Health & science medicalxpress.com 1 viewFDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
- Health & science france24.com 1 viewWHO warns drug resistance is outpacing the world's response
- Health & science fiercepharma.com 1 viewGSK's Nelkarmi wins FDA nod for ALK lung cancer, capping a three-approval run

